BD ProbeTec ET recall
This article was originally published in The Gray Sheet
Executive SummaryFirm's voluntary corrective action for Chlamydia/gonorrhea urine processing kits is deemed Class I recall. BD initiated the field action Jan. 10, following user complaints of indeterminate results from urine specimens stored with a urine processing pouch at refrigerated temperatures. BD's investigation concluded that a single lot of raw material used to manufacture pouches distributed between February and August 2004 sparked the problem. BD also found that a failure to use the amplification control during testing increases the risk of false negative results. The company notified customers worldwide by telephone and mail and adopted additional quality inspection and testing to ensure proper functioning of all other products...
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.